BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 11805282)

  • 1. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.
    Heessen S; Leonchiks A; Issaeva N; Sharipo A; Selivanova G; Masucci MG; Dantuma NP
    Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1532-7. PubMed ID: 11805282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation.
    Rodriguez MS; Desterro JM; Lain S; Lane DP; Hay RT
    Mol Cell Biol; 2000 Nov; 20(22):8458-67. PubMed ID: 11046142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of proteasomal degradation by the gly-Ala repeat of Epstein-Barr virus is influenced by the length of the repeat and the strength of the degradation signal.
    Dantuma NP; Heessen S; Lindsten K; Jellne M; Masucci MG
    Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8381-5. PubMed ID: 10890896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1.
    Asher G; Lotem J; Sachs L; Kahana C; Shaul Y
    Proc Natl Acad Sci U S A; 2002 Oct; 99(20):13125-30. PubMed ID: 12232053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of p53 by Mdm2: fate is in the numbers.
    Shmueli A; Oren M
    Mol Cell; 2004 Jan; 13(1):4-5. PubMed ID: 14731389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.
    Brignone C; Bradley KE; Kisselev AF; Grossman SR
    Oncogene; 2004 May; 23(23):4121-9. PubMed ID: 15064742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation.
    Zaika A; Marchenko N; Moll UM
    J Biol Chem; 1999 Sep; 274(39):27474-80. PubMed ID: 10488081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mdm2 binds p73 alpha without targeting degradation.
    Bálint E; Bates S; Vousden KH
    Oncogene; 1999 Jul; 18(27):3923-9. PubMed ID: 10435614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation.
    Jin Y; Lee H; Zeng SX; Dai MS; Lu H
    EMBO J; 2003 Dec; 22(23):6365-77. PubMed ID: 14633995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeat sequence of Epstein-Barr virus-encoded nuclear antigen 1 protein interrupts proteasome substrate processing.
    Zhang M; Coffino P
    J Biol Chem; 2004 Mar; 279(10):8635-41. PubMed ID: 14688254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53.
    Rajendra R; Malegaonkar D; Pungaliya P; Marshall H; Rasheed Z; Brownell J; Liu LF; Lutzker S; Saleem A; Rubin EH
    J Biol Chem; 2004 Aug; 279(35):36440-4. PubMed ID: 15247280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts.
    Gentiletti F; Mancini F; D'Angelo M; Sacchi A; Pontecorvi A; Jochemsen AG; Moretti F
    Oncogene; 2002 Jan; 21(6):867-77. PubMed ID: 11840332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway.
    Chang YC; Lee YS; Tejima T; Tanaka K; Omura S; Heintz NH; Mitsui Y; Magae J
    Cell Growth Differ; 1998 Jan; 9(1):79-84. PubMed ID: 9438391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.
    Fang S; Jensen JP; Ludwig RL; Vousden KH; Weissman AM
    J Biol Chem; 2000 Mar; 275(12):8945-51. PubMed ID: 10722742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ubiquitin ligase COP1 is a critical negative regulator of p53.
    Dornan D; Wertz I; Shimizu H; Arnott D; Frantz GD; Dowd P; O'Rourke K; Koeppen H; Dixit VM
    Nature; 2004 May; 429(6987):86-92. PubMed ID: 15103385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1.
    Asher G; Lotem J; Tsvetkov P; Reiss V; Sachs L; Shaul Y
    Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15065-70. PubMed ID: 14634213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins.
    Park JS; Kim EJ; Lee JY; Sin HS; Namkoong SE; Um SJ
    Int J Cancer; 2001 Mar; 91(6):822-7. PubMed ID: 11275986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pathway regulating MDM2 protein degradation can be altered in human leukemic cells.
    Pan Y; Haines DS
    Cancer Res; 1999 May; 59(9):2064-7. PubMed ID: 10232588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.
    Xirodimas DP; Stephen CW; Lane DP
    Exp Cell Res; 2001 Oct; 270(1):66-77. PubMed ID: 11597128
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding.
    Wang W; Takimoto R; Rastinejad F; El-Deiry WS
    Mol Cell Biol; 2003 Mar; 23(6):2171-81. PubMed ID: 12612087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.